Polyoxazoline-lipid conjugates and lipid nanoparticles and pharmaceutical compositions including same
US12233132B2 · kind B2 · utility
0Cited by
8References
22Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 4, 2022 |
| Grant date | Feb 25, 2025 |
| Priority date | — |
| Expiry date | May 23, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N15/88
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
POZ-lipid conjugates and lipid nanoparticles (LNPs) including POZ-lipid conjugates used to facilitate delivery of an encapsulated payload. LNPs including POZ-lipid conjugates and a nucleic acid payload such as, but not limited to, mRNA or modified mRNA are disclosed. Such LNPs have no immunogenicity or reduced immunogenicity as compared to a corresponding LNP containing a PEG-lipid.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.